BeiGene ends pact with Shoreline, its 'entry into cell therapy'

Kyle LaHucik

Senior Reporter

BeiGene said its four-target natural killer cell therapy collaboration with Shoreline Biosciences is over. And by reneging on Shoreline’s iPSC-NK cell technology, BeiGene loses its “entry into cell therapy,” a phrase used to describe the tie-up in an investor presentation last year.

BeiGene, which reported that revenue in 2023 was 74% higher than in 2022, said Monday the pact was terminated earlier this year. The biotech had initially doled out $45 million upfront in January 2022, after the partners disclosed the agreement in June 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

BeiGene ends pact with Shoreline, its 'entry into cell therapy'

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

The next generation of AI biotechs is here. Can they deliver on the hype?

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

Sanders presses pharma leaders to change stance on Pandemic Accord proposals

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

BeiGene ends pact with Shore­line, its 'en­try in­to cell ther­a­py'

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

more like this

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Bris­tol My­ers to shut­ter Bay Area cell ther­a­py R&D fa­cil­i­ty as it elim­i­nates jobs and costs

Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

Sanders press­es phar­ma lead­ers to change stance on Pan­dem­ic Ac­cord pro­pos­als

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

BeiGene ends pact with Shoreline, its 'entry into cell therapy'

The next generation of AI biotechs is here. Can they deliver on the hype?

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

Sanders presses pharma leaders to change stance on Pandemic Accord proposals

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs